Pembrolizumab Plus Chemo Boosts Response in Triple-Negative Breast Cancer
Adding the immunotherapy pembrolizumab to neoadjuvant chemotherapy improved the pathological complete response rate in patients with early triple-negative breast cancer, according to findings of a study presented at ESMO.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Legislation | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Study